Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
FibroGen, Inc.
FibroGen Announces New Research at Stanford University School of Medicine Indicates That Inhibiting CTGF Could Have Therapeutic Benefits in Treating Pancreatic Cancer
February 17th, 2009
FibroGen, Inc. announced that new research reported by scientists at Stanford University School of Medicine demonstrates a critical role for connective tissue growth factor (CTGF) in the growth of pancreatic cancer tumors. The research showed that tumor growth in mice could be completely prevented by blocking the expression of tumor cell-derived CTGF and that tumor cell survival was compromised under conditions of hypoxic stress in vitro when CTGF levels were low. The findings are supportive of an ongoing phase 1 study of FG-3019, FibroGen’s fully human monoclonal antibody against CTGF, in patients with pancreatic cancer. “The data indicate that inhibiting the...
Source: Cancer Weekly (2009-02-17)
|
